An2 Therapeutics Stock Buy Hold or Sell Recommendation
| ANTX Stock | USD 1.23 0.07 5.38% |
Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding AN2 Therapeutics is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell AN2 Therapeutics given historical horizon and risk tolerance towards AN2 Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for AN2 Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out AN2 Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide. In addition, we conduct extensive research on individual companies such as AN2 and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards AN2 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
AN2 |
Execute AN2 Therapeutics Buy or Sell Advice
The AN2 recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on AN2 Therapeutics. Macroaxis does not own or have any residual interests in AN2 Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute AN2 Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Modest | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
AN2 Therapeutics Trading Alerts and Improvement Suggestions
| AN2 Therapeutics may become a speculative penny stock | |
| AN2 Therapeutics had very high historical volatility over the last 90 days | |
| AN2 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AN2 Therapeutics currently holds about 113.39 M in cash with (53.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| AN2 Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: NationSwell Recognized with Five Anthem Awards for Transformative Social Impact Initiatives |
AN2 Therapeutics Returns Distribution Density
The distribution of AN2 Therapeutics' historical returns is an attempt to chart the uncertainty of AN2 Therapeutics' future price movements. The chart of the probability distribution of AN2 Therapeutics daily returns describes the distribution of returns around its average expected value. We use AN2 Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of AN2 Therapeutics returns is essential to provide solid investment advice for AN2 Therapeutics.
| Mean Return | 0.38 | Value At Risk | -2.83 | Potential Upside | 3.64 | Standard Deviation | 3.43 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of AN2 Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
AN2 Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as AN2 Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading AN2 Therapeutics back and forth among themselves.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 224.2 K | Ghost Tree Capital, Llc | 2024-06-30 | 219.3 K | Nantahala Capital Management, Llc | 2024-06-30 | 196.6 K | Geode Capital Management, Llc | 2024-06-30 | 180.9 K | Two Sigma Advisers, Llc | 2024-06-30 | 134.7 K | Two Sigma Investments Llc | 2024-06-30 | 132.1 K | Bridgeway Capital Management, Llc | 2024-06-30 | 104.3 K | Aldebaran Capital Llc | 2024-09-30 | 100.5 K | Alyeska Investment Group, L.p. | 2024-06-30 | 100 K | Bml Capital Management Llc | 2024-09-30 | 5.7 M | Ra Capital Management, Llc | 2024-06-30 | 5.6 M |
AN2 Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to AN2 Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that AN2 Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a AN2 stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.31 | |
β | Beta against Dow Jones | 0.69 | |
σ | Overall volatility | 3.51 | |
Ir | Information ratio | 0.08 |
AN2 Therapeutics Volatility Alert
AN2 Therapeutics currently demonstrates below-average downside deviation. It has Information Ratio of 0.08 and Jensen Alpha of 0.31. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure AN2 Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact AN2 Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.AN2 Therapeutics Fundamentals Vs Peers
Comparing AN2 Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze AN2 Therapeutics' direct or indirect competition across all of the common fundamentals between AN2 Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as AN2 Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of AN2 Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing AN2 Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare AN2 Therapeutics to competition |
| Fundamentals | AN2 Therapeutics | Peer Average |
| Return On Equity | -0.69 | -0.31 |
| Return On Asset | -0.43 | -0.14 |
| Current Valuation | (56.4 M) | 16.62 B |
| Shares Outstanding | 29.88 M | 571.82 M |
| Shares Owned By Insiders | 21.63 % | 10.09 % |
| Shares Owned By Institutions | 52.31 % | 39.21 % |
| Number Of Shares Shorted | 133.57 K | 4.71 M |
| Price To Earning | 3.96 X | 28.72 X |
| Price To Book | 0.44 X | 9.51 X |
| EBITDA | 4.9 M | 3.9 B |
| Net Income | (64.73 M) | 570.98 M |
| Cash And Equivalents | 113.39 M | 2.7 B |
| Cash Per Share | 5.84 X | 5.01 X |
| Total Debt | 14.04 M | 5.32 B |
| Current Ratio | 28.17 X | 2.16 X |
| Book Value Per Share | 4.19 X | 1.93 K |
| Cash Flow From Operations | (53.29 M) | 971.22 M |
| Short Ratio | 0.82 X | 4.00 X |
| Earnings Per Share | (1.99) X | 3.12 X |
| Target Price | 2.67 | |
| Number Of Employees | 41 | 18.84 K |
| Beta | -0.22 | -0.15 |
| Market Capitalization | 38.84 M | 19.03 B |
| Total Asset | 138.74 M | 29.47 B |
| Retained Earnings | (154.46 M) | 9.33 B |
| Working Capital | 96.46 M | 1.48 B |
| Net Asset | 138.74 M |
Note: Acquisition by Day Lucy of 27500 shares of AN2 Therapeutics subject to Rule 16b-3 [view details]
AN2 Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as AN2 . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About AN2 Therapeutics Buy or Sell Advice
When is the right time to buy or sell AN2 Therapeutics? Buying financial instruments such as AN2 Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having AN2 Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 257 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.